CAR T-Cell Therapy gets Orphan Drug Designation for Acute Lymphoblastic Leukemia
The cell therapy is approved for B-cell non-Hodgkin lymphoma and B-ALL in China.
This content originally appeared on our sister site, Targeted Oncology.
The FDA has granted orphan drug designation (ODD) to IASO Biotherapeutics' CT120 for the treatment of acute lymphoblastic leukemia.1
"CT120 is the first dual-targeted CAR-T cell therapy. The ODD granted to CT120 demonstrates the FDA's recognition and expectation of the product. CT120 has obtained two investigation new drug approvals for B-cell non-Hodgkin lymphoma [B-NHL] and B-ALL in China, and the clinical trial for the treatment of B-NHL is going well, said Wen (Maxwell) Wang, MD, PhD, in the press release.
CT120 is a fully human CD19/CD22 dual-targeted chimeric antigen receptor (CAR)-T cell therapy. It reduces the Antibody-drug antibody effect and improves the viability of CAR-T cells by binding to tumor cells expressing CD19 and CD22.
A single-armed, open-label, multicenter phase 1/2 study of CT120 for the treatment of patients with relapsed or refractory B-NHL. The study has a target enrollment of 125 patients who will be assessed for the coprimary end points of the incidence of dose-limiting toxicities and the incidence of adverse events in the phase 1 portion and overall response rate (ORR)at day 90 during phase 2. The secondary end points of the study include ORR, time to response, time to complete response, duration of response, progression-free survival, overall survival, the quantity of CAR copies in peripheral blood, the quantity of CAR T-cells level in peripheral blood, laboratory tests, vital signs, and physical examinations.2
READ MORE: Posoleucel for Virus-Associated Hemorrhagic Cystitis Receives Orphan Drug Designation
To execute the study, investigators will conduct a leukapheresis to manufacture the CAR T cells.. The study protocol allowed for bridging therapy between peripheral blood mononuclear cell collection and lymphodepletion. Lymphodepletion with fludarabine and cyclophosphamide was performed for 3 consecutive days followed by 1 day of rest before receipt of CT120. Patients are infused with either 1.0 x 106 CAR-positive T cells/kg, 3.0 x 106 CAR-positive T cells/kg, or 6.0 x 106 CAR-positive T cells/kg.
Follow-up of patients in the study will go on for a minimum of 2 years after the final infusion of CT120. Long-term safety follow-up will continue for up to 15 years after the final infusion of CAR T cells in the study.
Patients are eligible to enroll given they are between the ages of 18 and 70 years old with pathologically confirmed B-NHL. Patients are also required to have at least 1 measurable lesion and a life expectancy of at least 12 weeks.
"The company is advancing the development of the product in China and United States. We look forward to the launch of this innovative therapy to cure more patients," said Wang, in the press release.
The ODD is expected to help with the development of CT120 in the United States.1
